MIMS Group Expanded Global Operations and Product Suite
Healthcare platform operators should note the company's shift toward AI-driven clinical tools and new market entry.
Updated on Sept. 28, 2026 in Healthcare
Live Poll
Do you trust that digitizing medical decision-making tools makes clinical workflows safer for healthcare professionals?
MIMS Group has launched its MIMS Pulse clinical decision support platform and initiated a strategy to expand its medical communications business into the US and UK markets. The firm is pivoting its long-standing repository of medical data into technology-enabled content services to scale across its 17 global markets.
Why it matters
The transition from traditional medical data to AI-enabled platforms reflects a broader competitive push to standardize clinical decision support services globally. By scaling into new regions and specialties, the company aims to leverage its existing base of 2 million healthcare professional subscribers.
MIMS Group currently serves 2 million healthcare professional subscribers across 17 global markets. This reach is underpinned by six decades of medical data, now being integrated into new clinical modules and AI-enabled platforms.
The players
MIMS Group
A Singapore-based healthcare information provider that leverages six decades of clinical data to offer decision support services to medical professionals.
Sohil Goswami
The Group CEO of MIMS Group who was appointed in January 2026 to lead the company's transition into AI-enabled technology platforms.
The details
MIMS is modernizing its legacy content delivery by transitioning its databases into the MIMS Pulse clinical decision support platform. This strategy involves scaling its existing eMIMS Plus tool further into Southeast Asia while simultaneously deploying new healthcare categories through the Drugs4Dent initiative. The firm is also applying AI-enabled content capabilities to standardize workflows and enhance customer engagement models across its international footprint.
Timeline
MIMS Group was established in 1963.
Sohil Goswami was appointed Group CEO in January 2026.
MIMS announced its product and international growth strategy on September 28, 2026.
Market Landscape
The strategy marks an acceleration of the industry-wide digital transformation of clinical decision support systems by shifting legacy data into scalable AI platforms. This move follows a documented trend of providers seeking to capture global scale by moving beyond local medical information databases.
Operators in clinical content should watch for the integration of MIMS Pulse as a new benchmark for how legacy databases are monetized through AI. Competitive pressure will likely increase for regional players as MIMS scales its tech-enabled services across Asia, the US, and the UK.
The takeaway
The pivot from information repository to software-as-a-service provider highlights the necessity of AI-integration for firms relying on archival healthcare data. Operators should monitor the rollout of the Drugs4Dent category as a signal for potential consolidation or expansion opportunities in niche clinical verticals.
Further reading
For broader trends in the sector, explore the latest developments in Healthcare.
Live Poll
Do you trust that digitizing medical decision-making tools makes clinical workflows safer for healthcare professionals?
